Hence, Nuo Therapeutics's Capex-to-Revenue for the
three
months ended in Sep. 2024 was 0.00.
Nuo Therapeutics Capex-to-Revenue Historical Data
The historical data trend for Nuo Therapeutics's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuo Therapeutics's Capex-to-Revenue
For the Biotechnology subindustry, Nuo Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Capex-to-Revenue falls into.
Nuo Therapeutics Capex-to-Revenue Calculation
Nuo Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (OTCPK:AURX) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Nuo Therapeutics Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nuo Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AURX has been successfully added to your 